Loading clinical trials…
Loading clinical trials…
Clinical trials · failure tracking
Oncology studies whose overall status is TERMINATED, WITHDRAWN or SUSPENDED on ClinicalTrials.gov, with the stop reason exactly as the registrant posted it. A category is attached only when an explicit keyword rule matches the text; CancerIndex never infers why a study stopped.
5 stopped studies mapped to Diffuse Midline Glioma, H3 K27-Altered and descendants · 100% state a reason
Over the 5 studies matching the cancer, status and year filters (the category filter does not change this chart). Each study is counted once, in the first matching category; greyed bars are studies whose text matched no rule or was empty.
Computedrules ci-stop-reasons-v1 · keyword matching only
A category is assigned when one of its keywords appears in the posted text (case-insensitive, whole words). Rules are tested in this order and the first match wins; every match is kept in the API (reasonMatches).
| NCT | Title | Phase | Status | First posted | Lead sponsor | Why stopped (as posted) | Category |
|---|---|---|---|---|---|---|---|
| NCT05478837 | Genetically Modified Cells (KIND T Cells) for the Treatment of HLA-A*0201-Positive…(PNOC018) | Phase 1 | terminated | Jul 28, 2022 | University of California, San Francisco | Logistical issues | Other (stated, no rule matched) |
| NCT06806228 | Phase I Pilot Study to Evaluate the Anti-glioblastoma Effect of S-Gboxin in Standard… | Phase 1 | suspended | Feb 4, 2025 | Petrov, Andrey | The study protocol will be changed | Other (stated, no rule matched) |
| NCT04804709 | Non-Invasive Focused Ultrasound (FUS) With Oral Panobinostat in Children With Progressive… | Phase 1 | terminated | Mar 18, 2021 | Columbia University | FDA withdrew approval of the new drug application (NDA) for panobinostat as of March 24, 2022… | Sponsor / business decision |
| NCT05500508 | Oral AMXT 1501 Dicaprate in Combination With IV DFMO | Phase 1 / Phase 2 | terminated | Aug 15, 2022 | Aminex Therapeutics, Inc. | Required re-formulation of DFMO from IV to capsule to maintain safety | Safety / toxicity |
| NCT04771897 | A Study of BXQ-350 in Children With Newly Diagnosed Diffuse Intrinsic Pontine Glioma…(KONQUER) | Phase 1 | terminated | Feb 25, 2021 | Bexion Pharmaceuticals, Inc. | Bexion Pharmaceuticals has decided to close the BXQ-350.AD study to enrollment prior to the… | Enrollment / accrual |
Stop reasons are registrant-reported free text and are displayed verbatim (truncated; hover for the full text). Categories come from explicit keyword rules and are never inferred from the study design, sponsor or outcome; a study that stopped for several reasons is filed under the first rule that matched. A TERMINATED status does not imply a negative result.
Data updated 22 days agoSource updated Jul 13, 2026source: clinicaltrials